Related Articles

Symbicort combines budesonide, a corticosteroid, and formoterol fumarate dihydrate, a long-acting beta-2 agonist (LABA). It is already approved as maintenance treatment for asthma in patients ≥6 years old not adequately controlled on other asthma-controller medications (eg, low-medium dose inhaled corticosteroids) or those whose disease severity clearly warrants starting treatment with two maintenance therapies; and as maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and emphysema.

It is available as 80/4.5mcg and 160/4.5mcg strength inhalers; only the 160/4.5mcg strength is indicated for use in COPD conditions.